May 5, 2020 / By Kayla Rivas | Fox News
The first doses of a coronavirus vaccine have been injected into human patients, Pfizer Inc. and BioNTech announced on Tuesday.
The first dosing of the BNT162 vaccine program began in Germany last week, according to a company statement. The trial phase aims to enroll up to 360 patients, ages 18 to 55. Once the younger group produces sound evidence of safety and immunogenicity, testing in older adults, or those between the ages of 65 and 85, will begin.
“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” said Albert Bourla, Pfizer CEO and chairman, in the statement.
Sites dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine.
